Fingolimod Uses, Side Effects & Warnings - Drugs.com
2023年6月22日 · Fingolimod is used in adults and children at least 10 years old to treat relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease). Fingolimod may also be used for purposes not listed in this medication guide.
Fingolimod - Wikipedia
Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. It has been reported to reduce the rate of relapses in relapsing-remitting multiple sclerosis by approximately one-half over a two-year period.
芬戈莫德 - 百度百科
芬戈莫德为首个防止淋巴细胞从淋巴结中离开的鞘氨醇1-磷酸盐受体调节剂类药，降低多发性硬化症患者疾病复发的频率，延缓多发性硬化症患者的病情恶化程度。 它还可以保持淋巴结内特定的免疫细胞，防止它们作用于中枢神经系统并造成损害，并且对淋巴细胞的保持力是可逆的，从而使患者在治疗停止后体内循环的淋巴细胞恢复到正常水平 [2]。 0.5 mg硬胶囊. 二是调节神经细胞的S1P受体。 [2] 芬戈莫德是一种神经鞘氨醇1-磷酸受体调节剂适用于复发性多发性硬化症患者 …
Fingolimod (oral route) - Mayo Clinic
2024年2月1日 · Fingolimod is used to treat the relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This medicine will not cure MS, but it may slow some disabling effects and decrease the number of relapses of the disease.
Fingolimod - StatPearls - NCBI Bookshelf
2024年5月30日 · Fingolimod is the first oral disease-modifying agent approved by the US Food and Drug Administration (FDA) for treating relapsing-remitting multiple sclerosis (RRMS).[1] This drug is also indicated for active secondary progressive disease with superimposed relapse and for treating clinically isolated syndromes.[2][3]
芬戈莫德（Gilenya，Fingolimod）FDA官方说明书 - 知乎
芬戈莫德是一种神经鞘氨醇1-磷酸受体调节剂适用于复发性多发性硬化症患者的治疗减少临床加重的频数和延缓身体残疾的积蓄。 (1) 剂量和给药方法. （1）推荐剂量：0.5 mg口服每天1次，有或无食物。 (2) 1）首次剂量后观察所有患者心动过缓的体征和症状至少6小时，每小时脉搏和血压测量。 在给药前和观察期结束时获得ECG。
Fingolimod: MedlinePlus Drug Information
Fingolimod is used to prevent episodes of symptoms and slow the worsening of disability in adults and children 10 years of age and older with relapsing-remitting forms (course of disease where symptoms flare up from time to time) of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness,...
GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting...
现代医药典范——芬戈莫德 发现与改进之路【新冠感染免疫损伤之 …
藤田（Fujita）后续对原始的多球壳菌素进行 不断的药学结构改进 得到的 机理类似但毒性大大降低 的新型免疫抑制剂小分子药—— 这就是芬戈莫德（Fingolimod，FTY720），商品名捷灵亚（Gilenya）。 确定一个天然化合物是否有效，需要有严格的评判标准。 屠呦呦先生在诺贝尔奖演讲 [1] 中对当时#191号样本进行评价时有一段话—— 1971年9月，重新设计了提取方法，改用低温提取，用乙醚回流或冷浸，而后用碱溶液除掉酸性部位的方法制备样品。 1971年10月4日，青 …
Fingolimod | C19H33NO2 | CID 107970 - PubChem
Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.